UP780, A chromone-enriched aloe composition improves insulin sensitivity

Metabolic Syndrome and Related Disorders

Volumn 11, Issue 4, 2013, Pages 267-275

  Yimam, Mesfin ^a   Zhao, Jifu ^a   Corneliusen, Brandon ^a   Pantier, Mandee ^a   Brownell, Lidia Alfaro ^a   Jia, Qi ^a  

^a Unigen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHROMONE DERIVATIVE; GLUCOSE; INSULIN; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; POLYSACCHARIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UP 780;

ALOE VERA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFICACY; FEEDING; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

3T3-L1 CELLS; ADIPONECTIN; ALOE; ANIMALS; BENZOPHENONES; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; CHROMONES; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; GLUCOSIDES; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; PHYTOTHERAPY; PLANT PREPARATIONS; POLYSACCHARIDES; TYROSINE;

EID: 84880433124     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2012.0135     Document Type: Article

References (39)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
2. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-2374.
3. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 2000;106: 459-465.
4. Mazzola N. Review of current and emerging therapies in type 2 diabetes mellitus. Am J Manag Care 2012;18(1 Suppl): S17-S26.
5. Munro N, Feher MD. Current, new, and emerging therapies for managing hyperglycaemia in type 2 diabetes. Br J Gen Pract 2008;58:531-533.
6. Stern MP. Strategies and prospects for finding insulin resistance genes. J Clin Invest 2000;106:323-327.
7. Hinnen D, Nielsen LL, Waninger A, et al. Incretin mimetics and DPP-IV inhibitors: New paradigms for the treatment of type 2 diabetes. J Am Board Fam Med 2006; 19:612-620.
8. Paisley AJ, Yadav R, Younis N, et al. Dapagliflozin: A review on efficacy, clinical effectiveness and safety. Expert Opin Investig Drugs. 2013;22:131-140.
9. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-435.
10. Perry C, Petrie Jr. Insulin-sensitising agents. Emerging Drugs 1998;3:247-260.
11. Willson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationship between peroxisome proliferator-activated receptor g agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665-668.
12. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: Incidence, pathophysiology, and clinical implications. Endocr Pract 2003;9: 406-416.
13. Hampton T. Diabetes drugs tied to fractures in women. JAMA 2007;297:1645.
14. Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf 2001;10:537-547.
15. Janke J, Engeli S, Boschmann M, et al. Retinol-binding protein 4 in human obesity. Diabetes 2006;55:2805-2810.
16. Lau DC, Dhillon B, Yan H, et al. Adipokines: Molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005;288:H2031-H2041.
17. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50: 2094-2099.
18. Surwit RS, Kuhn CM, Cochrane C, et al. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 1988;37:1163-1167.
19. Brown KK, Henke BR, Blanchard SG, et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor- gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999;48:1415-1424.
20. Way JM, Go?rgu? n CZ, Tong Q, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001;276:25651- 25653.
21. Gallou-Kabani C, Vigé A, Gross MS, et al. C57BL/6J and A/ J mice fed a high-fat diet delineate components of metabolic syndrome. Obesity (Silver Spring) 2007;15:1996-2005.
22. Attele AS, Zhou YP, Xie JT, et al. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 2002;51:1851-1858.
23. Harach T, Aprikian O,Monnard I, et al. Rosemary (Rosmarinus officinalis L.) leaf extract limits weight gain and liver steatosis in mice fed a high-fat diet. Planta Med 2010;76:566-571.
24. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
25. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002;147: 173-180.
26. Matsubara M. Plasma adiponectin decrease in women with nonalcoholic fatty liver. Endocr J 2004;51:587-593.
27. Ajabnoor MA. Effect of Aloes on blood glucose levels in normal and alloxan diabetic mice. J Ethnopharmacol 1990;28: 215-220.
28. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARg agonists: A potential mechanism of insulin sensitization. Endocrinology 2002;143:998-1007.
29. Rajasekaran S, Sivagnanam K, Subramanian S. Antioxidant effect of Aloe vera gel extract in streptozotocin-induced diabetes in rats. Pharmacol Rep 2005;57:90-96.
30. Rajasekaran S, Ravi K, Sivagnanam K, et al. Beneficial effects of Aloe vera leaf gel extract on lipid profile status in rats with streptozotocin diabetes. Clin Exp Pharmacol Physiol 2006;33: 232-237.
31. Tanaka M, Misawa E, Ito Y, et al. Identification of five phytosterols from Aloe vera gel as anti-diabetic compounds. Biol Pharm Bull 2006;29:1418-1422.
32. Al-Awadi F, Fatania H, Shamte U. The effect of a plants mixture extract on liver gluconeogenesis in streptozotocin induced diabetic rats. Diabetes Res 1991;18:163-168.
33. Parihar MS, Chaudhary M, Shetty R, et al. Susceptibility of hippocampus and cerebral cortex to oxidative damage in streptozotocin-treated mice: Prevention by extract of Withania somnifera and Aloe vera. J Clin Neurosci 2004;11: 397-402.
34. Bolkent S, Akev N, Ozsoy N, et al. Effect of Aloe vera (L.) Burm. Fil. leaf gel and pulp extracts on kidney in type-II diabetic rat models. Indian J Exp Biol 2004;42:48-52.
35. Can A, Akev N, Ozsoay N, et al. Effect of aloe vera leaf gel pulp on the liver in type II diabetic rats. Biol Pharm Bull 2004;27:694-698.
36. Rajasekaran S, Sivagnanam K, Subramanian S. Modulatory effects of Aloe vera leaf gel extract on oxidative stress in rats treated with streptozotocin. J Pharm Pharmacol 2005;57: 241-246.
37. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003;115(Suppl 8A):42S-48S.
38. Tang W, Zeve D, Seo J, et al. Thiazolidinediones regulate adipose lineage dynamics. Cell Metab 2011;14:116-122.
39. Devaraj S, Yimam M, Brownell L, et al. Effects of Aloe vera supplementation in subjects with pre-diabetes/metabolic syndrome. Metab Syndr Relat Disord 2012;10:319-386.